Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response..

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

(Print or Ty	pe Response	55)													
Name and Address of Reporting Person * Kolean Chad J			Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]					5. R	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 05/12/2016					X	X Officer (give title below) Other (specify below) VP, CFO and Treasurer					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
	N, WI 537										orm med by	More than One	Reporting Person		
(Cit	y)	(State)	(Zip)			Table I	- Non-	-Deriva	tive Securities	Acquired	, Disposed	l of, or Ben	eficially Owr	ed	
1.Title of S (Instr. 3)				Execution Date, if any (Month/Day/Year)		f Code (Inst		(A) (In		of (D) Own Trai	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		ed C	ownership orm: Direct (D)	Nature f Indirect eneficial wnership instr. 4)
									ed in this for					ie	
							c fo quired	orm dis	plays a curr sed of, or Bene	ently valid	d OMB co			e	
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	tion of Der Sec (A) Dis (D)	varrant Number rivative curities quired or posed o	quired s, option 6. D Exp (Mo	orm dis l, Dispos ons, con	splays a curred of, or Beneavertible securics and Date	ently valid	d OMB co	8. Price of	9. Number or Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficia Ownershi (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	5. 1 tion of Der (A) Dis (D) (In:	Varrant Number rivative curities quired or posed of	quired s, option 6. D Exp (Mo	, Disposons, con Date Exemplication I	splays a curred of, or Beneavertible securics and Date	ently valides officially Ovities) 7. Title an Amount of Underlyin Securities	d OMB co	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	of Indirect Beneficia Ownershi (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	s calls, we state the control of the	varrant Number rivative curities quired or posed of	quired s, optio 6. Exp (Mo	I, Disposons, con Date Exe Diration I Donth/Day	sed of, or Benevertible secur rcisable and Oate //Year)	ently valides officially Ovities) 7. Title an Amount of Underlyin Securities	d OMB co	8. Price of Derivative Security	9. Number or Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownership Form of Derivative Security: Direct (D) or Indirect	of Indirect Beneficia Ownershi (Instr. 4)

Reporting Owners

Donostino Ossar Norsa / Addisor	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Kolean Chad J C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON, WI 53716			VP, CFO and Treasurer			

Signatures

/s/ Chad Kolean	05/23/2016
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Options are not exercisable until stockholder approval of the increase of shares available for issuance under the plan. Options vest in equal quarterly increments over a period of three years from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.